THE 12th Sugiyama Laboratory Open Symposium

“Challenges and Opportunities of New Concepts and Tools for analyzing pharmacokinetics, drug delivery and pharmacodynamics.”

Date : Oct 16 (Tue) 13:40-17:55 , 2018

Place : RIKEN Yokohama Main Building Hall 

Language:English

Registration Fee : Free

    Banquet fee: \ 3,000 18:00-19:50

 

Registration ; mail to  yslab.secretary [at] ml.riken.jp with below information.

 

 name/affiliation/mail address/banquet(attend or not)

※ no later than Oct 10th, 2018 Japan time

 

※ We will inform all participants about the password for  viewing abstract.

 

 This Symposium is a part of the RIKEN Symposium Series.

Abstract

RIKEN Symposium 2018.pdf
PDFファイル 5.0 MB

Program

THE 12th RIKEN SYMPOSIUM.pdf
PDFファイル 58.6 KB

13:40-13:45    Opening remarks
                       Yuichi Sugiyama (Sugiyama Laboratory, RIKEN)

 

13:45-14:15    The application of QSP in Pharmaceutical Industry.

                       Akihiro Yamada (Astellas Pharma Inc.)

 

14:15-14:45    Advances in predicting pharmacokinetic drug-drug interactions.

                       Hiroyuki Kusuhara (The University of Tokyo / RIKEN)

 

14:45-15:15    Advances of quantitative proteomics for personalized therapies.

                       Sumio Ohtsuki (Kumamoto University / RIKEN)

 

15:15-15:35    Coffee break

 

15:35-16:25  【Plenary lecture】

                      Development of the integrated cancer medical system using artificial intelligence:                         Towards the realization of Precision Medicine.

                      Ryuji Hamamoto (National Cancer Center / RIKEN)

 

16:25-16:55    Intracellular environment-responsive material (ssPalm), as a technology for the                           DNA/RNA-based immune-engineering.

                       Hidetaka Akita (Chiba University)

 

16:55-17:10    In silico method for classifying drugs depending on clearance mechanism.

                       Yuichi Sugiyama (Sugiyama Laboratory, RIKEN)

 

17:10-17:40    In silico prediction of drug clearance mechanism by CPathPred at early drug discovery

                    stage.

                       Kimio Tohyama (Takeda Pharmaceutical Company Limited)

 

17:40-17:55    General Discussion

           Yuichi Sugiyama (Sugiyama Laboratory, RIKEN)

Contact to:Sugiyama's Laboratory
Email: yslab.secretary [at] ml.riken.jp
HP: http://www.sugiyamalab.com/
Tel: 045‐503‐9210